法国REISAMIC登记研究:免疫检查点抑制剂相关极重度irAEs的决定因素
本研究基于法国REISAMIC前瞻性登记研究,纳入2014年12月至2020年1月在Gustave Roussy研究所接受抗PD-1/PD-L1治疗的1187例成人实体瘤或血液肿瘤患者。结果显示380例(32.0%)发生至少1例irAE,34例(2.86%)发生极重度(IV-V级)irAEs;在380例irAE患者中,极重度irAEs占8.95%,死亡(V级)占3.95%。极重度irAEs发生时间更早(中位41天 vs 91天,p=0.01680),其预测因素包括体能状态≥2、中性粒细胞/淋巴细胞比值升高和肺癌治疗。
要点
- 极重度(IV-V级)irAEs发生更早,中位41天 vs 轻中度91天。
- 体能状态≥2、中性粒细胞/淋巴细胞比值升高和肺癌是极重度irAEs预测因素。
- 极重度irAEs占irAE患者的8.95%,死亡(V级)占3.95%。
核心结论
- 极重度(IV-V级)免疫毒性发生早于轻中度毒性。
- 免疫治疗开始时体能状态差、中性粒细胞/淋巴细胞比值升高和肺癌患者发生极重度毒性的风险较高。
研究设计与样本
- 法国REISAMIC登记研究为单中心前瞻性队列研究,在Gustave Roussy研究所开展。
- 2014年12月至2020年1月前瞻性随访1187例接受抗PD-1或抗PD-L1治疗的成人实体瘤或血液肿瘤患者。
- 纳入发生临床显著irAE的患者,分析极重度(IV-V级)irAEs的临床和实验室特征。
主要发现
- 1187例患者中380例(32.0%)发生至少1例irAE,34例(2.86%)发生极重度(IV-V级)irAEs。
- 380例irAE患者中,极重度(IV-V级)irAEs占8.95%,死亡(V级)占3.95%。
- 34例极重度irAEs患者中33例接受PD-1或PD-L1抑制剂单药治疗,1例接受PD-1联合CTLA-4抑制剂治疗。
- 极重度irAEs中位发生时间41天(四分位距0-634),轻中度(I-III级)为91天(0-1123),p=0.01680。
- 极重度irAEs预测因素为体能状态≥2、中性粒细胞/淋巴细胞比值升高和肺癌治疗。
关键数值与推荐
- 极重度irAEs定义为IV-V级免疫相关不良事件。
- 极重度irAEs发生更早:中位41天 vs 91天,p=0.01680。
- 预测因素包括体能状态≥2、中性粒细胞/淋巴细胞比值升高和肺癌。
临床怎么用
- 免疫治疗开始时评估体能状态和中性粒细胞/淋巴细胞比值,识别极重度irAEs高危患者。
- 对肺癌患者及体能状态≥2者应加强早期监测,因极重度irAEs发生更早。
- 研究结果有助于开发风险评分以识别极重度毒性高危患者。
局限性
- 单中心前瞻性队列研究,结果外推需谨慎。
- 极重度irAEs事件数较少(34例),预测因素分析可能受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune-related adverse events (irAEs) remain generally unpredictable, and severe irAEs remain challenging to detect early and manage. Very severe (grade IV-V) irAEs have not been extensively characterised in prospective studies, and their predictive factors remain unknown. OBJECTIVE: The objective of the study was to describe and identify predictive factors of very severe (grade IV-V) irAEs. DESIGN: The French Registre des Effets Indésirables Sévères des Anticorps Monoclonaux Immunomodulateurs en Cancérologie (REISAMIC) registry has prospectively collected all clinically significant irAEs occurring in patients treated with immune checkpoint inhibitors at Gustave Roussy Institute since 2014. SETTING: This was a single-centre prospective cohort study at the Gustave Roussy Institute cancer centre (Villejuif, France). PARTICIPANTS: The participants were all adult patients with a solid or haematological cancer treated with an anti-programmed cell death 1 (PD-1) or an anti-programmed cell death-ligand 1 (PD-L1) and who presented a clinically significant irAE. MAIN OUTCOMES AND MEASURES: The main outcomes included the clinical and laboratory characteristics of patients with very severe irAEs, including tumour type, affected organs, time to irAE occurrence, blood cell count and serum biochemistry parameters. RESULTS: Of the 1187 patients prospectively followed in REISAMIC between December 2014 and January 2020, 380 (32.0%) had at least one irAE, and 34 (2.86%) presented with very severe irAEs (grades IV-V). Among the 380 patients with an irAE, the distribution of very severe irAEs (grades IV-V) was 8.95% and death (grade V) was 3.95%. Among the 34 patients with very severe irAEs, 33 were treated with monotherapy of PD-1 or PD-L1 inhibitors, and one patient was treated with a combination of PD-1 and cytotoxic T-lymphocyte-associated protein 4 inhibitors. The median time to occurrence was shorter for very severe irAEs (median [interquartile range]: 41 days [0-634] for grades IV-V; versus 91 days [0-1123] for grades I-III; p = 0.01680). On initiation of immunotherapy, the predictive factors for very severe irAEs were performance status ≥2, elevated neutrophil/lymphocyte ratio and treatment for lung cancer. CONCLUSIONS: Very severe (grade IV-V) immunological toxicities occurred earlier than mild severe toxicities. On initiation of immunotherapy, patients with poor performance status, elevated neutrophil/lymphocyte ratio and lung cancer are identified at risk of developing these very severe toxicities. These results could help to develop risk scores to identify patients at risk of developing severe toxicities.
引用
- Ruste V, Goldschmidt V, Laparra A, et al. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry. Eur J Cancer. 2021. PMID: 34627664. doi:10.1016/j.ejca.2021.08.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。